Literature DB >> 17459353

AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.

Elisa Borsani1, Mauro Labanca, Rossella Bianchi, Luigi F Rodella.   

Abstract

Cannabinoids, such as anandamide, are involved in pain transmission. We evaluated the effects of AM404 (N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide), an anandamide reuptake inhibitor, monitoring the expression of c-fos, a marker of activated neurons and the pain-related behaviours using formalin test. The study was carried out in an experimental model of inflammatory pain made by a single injection of formalin in rat hind paws. Formalin test showed that the antinociceptive effect of AM404 was evident in phase I. We found that Fos-positive neurons in dorsal superficial and deep laminae of the lumbar spinal cord increased in formalin-injected animals and that AM404 significantly reduced Fos induction. Co-administration of cannabinoid CB(1) receptor antagonist (AM251), cannabinoid CB(2) receptor antagonist (AM630) and transient receptor potential vanilloid type 1 (TRPV-1) antagonist (capsazepine), attenuate the inhibitory effect of AM404 and this effect was higher using cannabinoid CB(2) and vanilloid TRPV-1 receptor antagonists. These results suggest that AM404 could be a useful drug to reduce inflammatory pain in our experimental model and that cannabinoid CB(2) receptor and vanilloid TRPV-1 receptor, and to a lesser extent, the cannabinoid CB(1) receptor are involved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459353     DOI: 10.1016/j.brainres.2007.03.071

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Targeting the endocannabinoid system in Alzheimer's disease.

Authors:  Jeremy Koppel; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 2.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

Review 3.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

4.  Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms.

Authors:  S Maione; E Morera; I Marabese; A Ligresti; L Luongo; G Ortar; V Di Marzo
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

5.  TRPV1 in brain is involved in acetaminophen-induced antinociception.

Authors:  Christophe Mallet; David A Barrière; Anna Ermund; Bo A G Jönsson; Alain Eschalier; Peter M Zygmunt; Edward D Högestätt
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

6.  AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity.

Authors:  Soraya Wilke Saliba; Ariel R Marcotegui; Ellen Fortwängler; Johannes Ditrich; Juan Carlos Perazzo; Eduardo Muñoz; Antônio Carlos Pinheiro de Oliveira; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2017-12-13       Impact factor: 8.322

Review 7.  Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action.

Authors:  Nobuko Ohashi; Tatsuro Kohno
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

8.  Repurposing AM404 for the treatment of oral infections by Porphyromonas gingivalis.

Authors:  Evelien Gerits; Pieter Spincemaille; Kaat De Cremer; Katrijn De Brucker; Serge Beullens; Karin Thevissen; Bruno P A Cammue; Katleen Vandamme; Maarten Fauvart; Natalie Verstraeten; Jan Michiels
Journal:  Clin Exp Dent Res       Date:  2017-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.